{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:53:28Z","timestamp":1790952808023,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104081","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:28:27Z","timestamp":1784795307000},"page":"104081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["AAV9-mediated GAA gene therapy following enzyme replacement therapy discontinuation in children with infantile-onset Pompe disease"],"prefix":"10.1016","volume":"98","author":[{"given":"Xinting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-2146","authenticated-orcid":false,"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9646","key":"10.1016\/j.eclinm.2026.104081_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eclinm.2026.104081_bib2","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa2407766","article-title":"AAV9-Mediated gene therapy for infantile-onset pompe's disease","volume":"392","author":"Ma","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2026.104081_bib3","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMe2506264","article-title":"Gene therapy for infantile-onset pompe's disease","volume":"392","author":"Parenti","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104081_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1399-0004.1996.tb03801.x","article-title":"Homozygous deletion of exon 18 leads to degradation of the lysosomal alpha-glucosidase precursor and to the infantile form of glycogen storage disease type II","volume":"49","author":"Ausems","year":"1996","journal-title":"Clin Genet"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104081_bib5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ymgme.2011.09.005","article-title":"Endoplasmic reticulum stress induces autophagy through activation of p38 MAPK in fibroblasts from Pompe disease patients carrying c.546G>T mutation","volume":"104","author":"Shimada","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104081_bib6","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1021\/jm3005543","article-title":"Discovery of a novel noniminosugar acid \u03b1 glucosidase chaperone series","volume":"55","author":"Xiao","year":"2012","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104081_bib7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","article-title":"Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction","volume":"105","author":"Coutinho","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104081_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2023.06.005","article-title":"Lysosomal enzyme trafficking: from molecular mechanisms to human diseases","volume":"34","author":"Braulke","year":"2024","journal-title":"Trends Cell Biol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104081_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104081_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: a comprehensive overview","volume":"7","author":"Peruzzo","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104081_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase-a guide for the treatment of Pompe disease","volume":"8","author":"Roig-Zamboni","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.104081_bib12","article-title":"Acid \u03b1-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: a systematic review","volume":"39","author":"Schoser","year":"2024","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104081_bib13","first-page":"42","article-title":"Glycogen storage disease type II: clinical overview","volume":"26","author":"Di Rocco","year":"2007","journal-title":"Acta Myol"},{"key":"10.1016\/j.eclinm.2026.104081_bib14","first-page":"45","article-title":"Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.eclinm.2026.104081_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/11795565251337900","article-title":"Latest advancements in treatment options for infantile-onset Pompe disease: a comprehensive narrative review","volume":"19","author":"Khan","year":"2025","journal-title":"Clin Med Insights Pediatr"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104081_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","article-title":"Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening","volume":"135","author":"Huggins","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104081_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13023-020-01353-4","article-title":"Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures","volume":"15","author":"Vanherpe","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104081_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/biom13091279","article-title":"A comprehensive update on late-onset pompe disease","volume":"13","author":"Labella","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104081_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104081_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JND-230164","article-title":"Long-term outcome of infantile onset pompe disease patients treated with enzyme replacement therapy - data from a German-Austrian cohort","volume":"11","author":"Pfrimmer","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104081_bib21","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1542\/neo.26-12-081","article-title":"Enzyme replacement therapy & other therapeutic frontiers in infantile metabolic disorders","volume":"26","author":"Choi","year":"2025","journal-title":"NeoReviews"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104081_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.eclinm.2026.104081_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13023-025-03679-3","article-title":"Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review","volume":"20","author":"Giugliani","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.eclinm.2026.104081_bib24","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/mt.2009.128","article-title":"A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells","volume":"17","author":"Smith","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.eclinm.2026.104081_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2013.08.010","article-title":"A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease","volume":"111","author":"Wang","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.eclinm.2026.104081_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mus.27854","article-title":"Validity and reliability of visual assessment of orofacial muscle ultrasound images using a modified Heckmatt scale","volume":"68","author":"Lagarde","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.eclinm.2026.104081_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mus.24149","article-title":"Blood-based diagnostic testing for Pompe disease: consistency between GAA enzyme activity in dried blood spots and GAA gene sequencing results","volume":"49","author":"Goldstein","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.eclinm.2026.104081_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.eclinm.2026.104081_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/picr.PICR_52_18","article-title":"Analysis of serious adverse event: writing a narrative","volume":"9","author":"Nambiar","year":"2018","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.eclinm.2026.104081_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008415","article-title":"Muscle ultrasound: a useful tool in newborn screening for infantile onset pompe disease","volume":"96","author":"Hwang","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104081_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101590","article-title":"Infantile-onset Pompe disease entering adulthood: insights from 2 decades of enzyme replacement therapy experience","volume":"27","author":"Regmi","year":"2025","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104081_bib32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/jmg-2022-108675","article-title":"Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme","volume":"60","author":"Yang","year":"2023","journal-title":"J Med Genet"},{"key":"10.1016\/j.eclinm.2026.104081_bib33","article-title":"Avalglucosidase alfa in infantile-onset Pompe disease: a snapshot of real-world experience in Italy","volume":"40","author":"Fiumara","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.eclinm.2026.104081_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104081_bib35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/gt.2013.16","article-title":"Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery","volume":"20","author":"Katwal","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.eclinm.2026.104081_bib36","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.omtm.2020.08.006","article-title":"High-resolution histological landscape of AAV DNA distribution in cellular compartments and tissues following local and systemic injection","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.eclinm.2026.104081_bib37","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/mus.880181414","article-title":"Glycogenosis type II (acid maltase deficiency)","volume":"3","author":"Reuser","year":"1995","journal-title":"Muscle Nerve Suppl"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104081_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience","volume":"29","author":"Ni\u00f1o","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.eclinm.2026.104081_bib39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1210\/jc.2009-2161","article-title":"Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects","volume":"95","author":"Minetto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2026.104081_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41580-025-00873-w","article-title":"Lysosomal membrane homeostasis and its importance in physiology and disease","volume":"27","author":"Radulovic","year":"2026","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.eclinm.2026.104081_bib41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00726-011-0877-3","article-title":"The creatine kinase system and pleiotropic effects of creatine","volume":"40","author":"Wallimann","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.eclinm.2026.104081_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41574-020-0365-5","article-title":"Creatine metabolism: energy homeostasis, immunity and cancer biology","volume":"16","author":"Kazak","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eclinm.2026.104081_bib43","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1113\/EP093049","article-title":"The skeletal muscle-adipose creatine metabolic axis: a novel paradigm for lipid metabolism reprogramming and obesity management","volume":"111","author":"Su","year":"2026","journal-title":"Exp Physiol"},{"key":"10.1016\/j.eclinm.2026.104081_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jimd.12344","article-title":"Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding","volume":"44","author":"Sidorina","year":"2021","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104081_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104081_bib46","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s13023-024-03373-w","article-title":"The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)","volume":"19","author":"Parenti","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.eclinm.2026.104081_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101899","article-title":"Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy","volume":"81","author":"Mu\u00f1oz","year":"2024","journal-title":"Mol Metab"},{"issue":"21-22","key":"10.1016\/j.eclinm.2026.104081_bib48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1177\/10430342251359989","article-title":"Long-term functional correction of pompe disease and increased \u03b1-glucosidase expression after gene therapy with novel combinations of muscle-targeted transcriptional cis-regulatory elements","volume":"36","author":"Pham","year":"2025","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104081_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101464","article-title":"A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease","volume":"33","author":"Sellier","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.eclinm.2026.104081_bib50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104081_bib51","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.eclinm.2026.104081_bib52","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104081_bib53","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/mt.2012.286","article-title":"Baculovirus: an insect-derived vector for diverse gene transfer applications","volume":"21","author":"Airenne","year":"2013","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104081_bib54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104081_bib55","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1128\/jvi.71.9.6816-6822.1997","article-title":"Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production","volume":"71","author":"Allen","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.eclinm.2026.104081_bib56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.omtm.2022.01.008","article-title":"Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps","volume":"24","author":"Brimble","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104081_bib57","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-025-04073-z","article-title":"Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy","volume":"32","author":"Buddle","year":"2026","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104081_bib58","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1097\/CCM.0b013e3181bc7bd5","article-title":"Why we should be wary of single-center trials","volume":"37","author":"Bellomo","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eclinm.2026.104081_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:25:36Z","timestamp":1787559936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"alternative-id":["S2589537026003342"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104081","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV9-mediated GAA gene therapy following enzyme replacement therapy discontinuation in children with infantile-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104081"}}